BridgeMD
The impact of vaccine platform, age and HIV infection on germinal centre formation.
EU CTIS ID: 2023-510354-16-00
What this study is testing
The primary objective of the trial will be to compare germinal centre formation after pneumococcal vaccination between different populations (health young vs healthy older adults; healthy young vs people living with HIV) as well as between different vaccine platforms.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age between 20 - 40 years or age > 60 years.
- Generally Healthy
- For PLWH group: aged 20 - 40 years, with documented HIV infection on active anti-retroviral therapy resulting in viral supression ( HIV copies < 200/ml)
You likely can't join if
- Pregnancy at time of inclusion
- Use of immunosuppressive medication
- Use of direct acting anticoagulant drugs (DOACs) or vitamin K antagonists
- Known hypersensitivity to vaccine components
- Recent (past month) surgery in axillar area or major surgery elsewhere
- Chronic nasal corticosteroid use (> 3 months)
See the full eligibility criteria
- Age between 20 - 40 years or age > 60 years.
- Generally Healthy
- For PLWH group: aged 20 - 40 years, with documented HIV infection on active anti-retroviral therapy resulting in viral supression ( HIV copies < 200/ml)
- Pregnancy at time of inclusion
- Use of immunosuppressive medication
- Use of direct acting anticoagulant drugs (DOACs) or vitamin K antagonists
- Known hypersensitivity to vaccine components
- Recent (past month) surgery in axillar area or major surgery elsewhere
- Chronic nasal corticosteroid use (> 3 months)
- History of severe nose bleeds
- Vaccination < 1 month before inclusion
- Fever at time of inclusion
- Inability to provide informed consent
- Inability to visit the LUMC for study procedures.
- Breastfeeding during the course of the study
- Prior documented pneumococcal vaccination
- Prior pneumococcal infection
- Documented primary immune disorder or primary coagulopathy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.